Non-small cell lung cancer (NSCLC). Malignant neoplasm of unspecified part of bronchus or lung
Conditions
Interventions
Intervention group: Novohil drug manufactured by Faran Chemical Factory with a dose of 450 mg (containing 400 mg of propolis and 50 mg of echinacea) is administered orally to patients twice a day for
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Lung cancer patients (NSCLC) consuming Pemetrexed
Exclusion criteria
Exclusion criteria: Patients who are allergic to medicine Patients with hypothyroidism Patients using hypnotics and neuroleptics Patients addicted to drugs Suffering from underlying nerve disorders Patients who need surgery Pregnant and lactating
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization rate. Timepoint: Before intervention and one month after the end of intervention. Method of measurement: Patient’s record.;Rate of infection. Timepoint: Before intervention and one month after the end of intervention. Method of measurement: Patient’s record. | — |
Primary
| Measure | Time frame |
|---|---|
| Quality of life score based on EQ-5D-3L questionnaire. Timepoint: Measuring the quality of life based on the EQ-5D-3L questionnaire on days 0 and 28. Method of measurement: EQ-5D-3L questionnaire.;Fatigue complication score based on BFI questionnaire. Timepoint: Measurement of fatigue complication score based on BFI questionnaire on days 0-7-14-21-28. Method of measurement: BFI questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza rahimi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed